Search results
Results from the WOW.Com Content Network
Treatments can be classified in two main subtypes: pharmacological and non-pharmacological. Pharmacological treatments vary greatly depending on the origin or type of dysfunction and some examples of the medications used are: [55] alfuzosin for retention, [56] trospium and flavoxate for urgency and incontinency, [57] [58] and desmopressin for ...
Palinopsia (Greek: palin for "again" and opsia for "seeing") is the persistent recurrence of a visual image after the stimulus has been removed. [1] Palinopsia is not a diagnosis; it is a diverse group of pathological visual symptoms with a wide variety of causes. Visual perseveration is synonymous with palinopsia.
The skeletal structure of norepinephrine The skeletal structure of dopamine. A norepinephrine–dopamine reuptake inhibitor (NDRI) is a drug used for the treatment of clinical depression, attention deficit hyperactivity disorder (ADHD), narcolepsy, and the management of Parkinson's disease.
2. Eat Smaller, More Frequent Meals. Instead of three main meals, try eating smaller, more frequent meals throughout the day. This can help if nausea is making it hard to feel like eating or if ...
The doctor can look for potential underlying causes, including dementia, medication effects, or environmental factors, Elhelou says. From there, they can suggest effective ways to help you manage ...
Typical symptoms of the disorder include halos or auras surrounding objects, trails following objects in motion, difficulty distinguishing between colors, apparent shifts in the hue of a given item, the illusion of movement in a static setting, visual snow, distortions in the dimensions of a perceived object, intensified hypnagogic and hypnopompic hallucinations, monocular double vision ...
“The most common symptoms we see in individuals are things like fatigue, brain fog, sleep disorders, joint aches, and a variety of gastrointestinal issues,” says Thomas Russo, M.D., a ...
[1] [2] These side effects are serious and some of them are permanent, and many remain a crucial concern for companies and healthcare professionals and substantial efforts are being encouraged to reduce the potential risks for future antipsychotics through more clinical trials and drug development.